Kennon McCollum, DNP, explains how multiday ES-SCLC chemotherapy regimens heighten myelosuppression risk and drive dose delays.
Optimizing Supportive Care in ES-SCLC: Managing Chemotherapy-Induced Myelosuppression
Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment regimens, locations, and more.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
Families of Children With ALL Face Extreme Financial Toxicity
3
Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib
4
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
5
